Risk management model in patients receiving therapy with biotechnological medications for rheumatoid arthritis in a medical center in Barranquilla, Colombia
- Pharmacy & Pharmacology International Journal
González J,1 Durán M,2 Durán J,3 Manrique E,4 Palacio B,4 Pereira I,5 Caballero E,5 Cabas E6
PDF Full Text
Introduction: Rheumatoid arthritis is an autoimmune, chronic and inflammatory disease that mainly the synovial membrane of the joints. Clinical features are pain, inflammation, heat and stiffness of the joints.
Objective: Identification of the problems related to the use of biotechnological medicines and the negative results associated with them.
Results: 78 patients (91.02% women and 9.8% men) were included where the most commonly used biological medicines were Etanercept (52.5%) Adalimumab (14.10) and Tocilizumab (15.3) and Tofacitinib (3.8%) Rituximab, Golimumab (5.12%) abatacept (3.84%) and certolizumab (1.84%). 96 NCO were identified in 49 patients of which 11 are problems of need, 28 effectiveness problems and 57 safety problems.
Conclusion: The identification of medication-related problems and the resolution and prevention of negative results associated with medication allows us to obtain better results in the pharmacotherapy of the patient, improving their quality of life.
rheumatoid arthritis, remission, DAS28, biological therapy